AD-3031

AD-3031 is an oral small molecule 5-alpha reductase inhibitor, specifically identified as finasteride, being utilized by Moogene Medi Co., Ltd. in the clinical development of its alopecia pipeline. It serves as the oral reference treatment in a Phase 1/2a clinical trial (NCT06114108) designed to compare its systemic pharmacokinetics and safety against AD-303A, a topical lipid nanoparticle (LNP) formulation of the same active ingredient. By inhibiting the enzyme 3-oxo-5-alpha-steroid 4-dehydrogenase 2, AD-3031 lowers the levels of dihydrotestosterone (DHT) in the scalp and serum, which is the primary hormone responsible for male pattern baldness. The use of AD-3031 in these trials is intended to demonstrate the potential advantages of the topical LNP delivery system in achieving localized therapeutic effects while minimizing the systemic side effects typically associated with oral 5-alpha reductase inhibitors.

Brand names

CaretopicFinjuve

Other names

finasteride